Akiram Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $552K

  • Investors
  • 7

Akiram Therapeutics General Information

Description

Developer of radiopharmaceuticals designed for advancing radiotherapeutics to treat solid tumors. The company is focused on designing and developing novel radioactive cancer-targeting molecules and pharmaceuticals for diagnostics and therapy, helping doctors visualize and treat aggressive cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Ihres väg 38
  • 752 63 Uppsala
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Ihres väg 38
  • 752 63 Uppsala
  • Sweden

Akiram Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akiram Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 24-Nov-2023 $552K Completed Pre-Clinical Trials
2. Early Stage VC 12-Jan-2023 Completed Pre-Clinical Trials
1. Early Stage VC 01-Jan-2022 Completed Pre-Clinical Trials
To view Akiram Therapeutics’s complete valuation and funding history, request access »

Akiram Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Akiram Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Akiram Therapeutics Patents

Akiram Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023274919-A1 Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers Pending 25-May-2022
EP-4532019-A2 Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers Pending 25-May-2022
WO-2023227644-A3 Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers Inactive 25-May-2022
US-20250340662-A1 Binding protein Pending 25-May-2022
WO-2023227644-A2 Binding protein Inactive 25-May-2022 C07K16/2884
To view Akiram Therapeutics’s complete patent history, request access »

Akiram Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akiram Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Erling Persson Family Foundation Limited Partner
3T Invest Venture Capital Minority
Linc (Sweden) Venture Capital Minority
Northislet Growth/Expansion Minority
Phase2Phase Biopharma Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Akiram Therapeutics FAQs

  • When was Akiram Therapeutics founded?

    Akiram Therapeutics was founded in 2021.

  • Where is Akiram Therapeutics headquartered?

    Akiram Therapeutics is headquartered in Uppsala, Sweden.

  • What is the size of Akiram Therapeutics?

    Akiram Therapeutics has 6 total employees.

  • What industry is Akiram Therapeutics in?

    Akiram Therapeutics’s primary industry is Drug Discovery.

  • Is Akiram Therapeutics a private or public company?

    Akiram Therapeutics is a Private company.

  • What is Akiram Therapeutics’s current revenue?

    The current revenue for Akiram Therapeutics is .

  • How much funding has Akiram Therapeutics raised over time?

    Akiram Therapeutics has raised $6.49M.

  • Who are Akiram Therapeutics’s investors?

    Erling Persson Family Foundation, 3T Invest, Linc (Sweden), Northislet, and Phase2Phase Biopharma are 5 of 7 investors who have invested in Akiram Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process